guest ::
| Home > Publications Database > Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibition. > print |
| Home > Publications Database > Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibition. > print |
| 001 | 155320 | ||
| 005 | 20230915094041.0 | ||
| 024 | 7 | _ | |a 2632-2498 |2 ISSN |
| 024 | 7 | _ | |a 10.1093/noajnl/vdaa115 |2 doi |
| 024 | 7 | _ | |a pmid:33134924 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC7592426 |2 pmc |
| 024 | 7 | _ | |a altmetric:93654761 |2 altmetric |
| 037 | _ | _ | |a DZNE-2021-00587 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Koch, Marilin Sophia |b 0 |
| 245 | _ | _ | |a Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibition. |
| 260 | _ | _ | |a Oxford |c 2020 |b Oxford University Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1683884205_24932 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a ISSN 2632-2498 not unique: **2 hits**. |
| 520 | _ | _ | |a The overexpression of (basic)helix-loop-helix ((b)HLH) transcription factors (TFs) is frequent in malignant glioma. We investigated molecular effects upon disruption of the (b)HLH network by a dominant-negative variant of the E47 protein (dnE47). Our goal was to identify novel molecular subgroup-specific therapeutic strategies.Glioma cell lines LN229, LNZ308, and GS-2/GS-9 were lentivirally transduced. Functional characterization included immunocytochemistry, immunoblots, cytotoxic, and clonogenic survival assays in vitro, and latency until neurological symptoms in vivo. Results of cap analysis gene expression and RNA-sequencing were further validated by immunoblot, flow cytometry, and functional assays in vitro.The induction of dnE47-RFP led to cytoplasmic sequestration of (b)HLH TFs and antiglioma activity in vitro and in vivo. Downstream molecular events, ie, alterations in transcription start site usage and in the transcriptome revealed enrichment of cancer-relevant pathways, particularly of the DNA damage response (DDR) pathway. Pharmacologic validation of this result using ataxia telangiectasia and Rad3 related (ATR) inhibition led to a significantly enhanced early and late apoptotic effect compared with temozolomide alone.Gliomas overexpressing (b)HLH TFs are sensitive toward inhibition of the ATR kinase. The combination of ATR inhibition plus temozolomide or radiation therapy in this molecular subgroup are warranted. |
| 536 | _ | _ | |a 345 - Population Studies and Genetics (POF3-345) |0 G:(DE-HGF)POF3-345 |c POF3-345 |f POF III |x 0 |
| 536 | _ | _ | |a 342 - Disease Mechanisms and Model Systems (POF3-342) |0 G:(DE-HGF)POF3-342 |c POF3-342 |f POF III |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a CAGE |2 Other |
| 650 | _ | 7 | |a DDR |2 Other |
| 650 | _ | 7 | |a E47 |2 Other |
| 650 | _ | 7 | |a RNA-Seq |2 Other |
| 650 | _ | 7 | |a bHLH transcription factors |2 Other |
| 700 | 1 | _ | |a Czemmel, Stefan |b 1 |
| 700 | 1 | _ | |a Lennartz, Felix |b 2 |
| 700 | 1 | _ | |a Beyeler, Sarah |b 3 |
| 700 | 1 | _ | |a Rajaraman, Srinath |b 4 |
| 700 | 1 | _ | |a Przystal, Justyna Magdalena |b 5 |
| 700 | 1 | _ | |a Govindarajan, Parameswari |b 6 |
| 700 | 1 | _ | |a Canjuga, Denis |b 7 |
| 700 | 1 | _ | |a Neumann, Manfred |b 8 |
| 700 | 1 | _ | |a Rizzu, Patrizia |0 P:(DE-2719)2810718 |b 9 |u dzne |
| 700 | 1 | _ | |a Zwirner, Stefan |b 10 |
| 700 | 1 | _ | |a Hoetker, Michael Stefan |b 11 |
| 700 | 1 | _ | |a Zender, Lars |b 12 |
| 700 | 1 | _ | |a Walter, Bianca |b 13 |
| 700 | 1 | _ | |a Tatagiba, Marcos |b 14 |
| 700 | 1 | _ | |a Raineteau, Olivier |b 15 |
| 700 | 1 | _ | |a Heutink, Peter |0 P:(DE-2719)2810728 |b 16 |u dzne |
| 700 | 1 | _ | |a Nahnsen, Sven |b 17 |
| 700 | 1 | _ | |a Tabatabai, Ghazaleh |b 18 |
| 773 | _ | _ | |a 10.1093/noajnl/vdaa115 |g Vol. 2, no. 1, p. vdaa115 |0 PERI:(DE-600)3009682-0 |n 1 |p vdaa115 |t Neuro-oncology advances |v 2 |y 2020 |x 2632-2498 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/155320/files/DZNE-2021-00587.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://pub.dzne.de/record/155320/files/DZNE-2021-00587.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:pub.dzne.de:155320 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)2810718 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 16 |6 P:(DE-2719)2810728 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-345 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Population Studies and Genetics |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-342 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Disease Mechanisms and Model Systems |x 1 |
| 913 | 2 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-354 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Prevention and Healthy Aging |x 0 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC (No Version) |0 LIC:(DE-HGF)CCBYNCNV |2 V:(DE-HGF) |b DOAJ |d 2020-09-05 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2020-09-05 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2020-09-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-09-23T13:25:59Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-09-23T13:25:59Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2022-09-23T13:25:59Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0112 |2 StatID |b Emerging Sources Citation Index |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2022-11-12 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-2719)1210009 |k AG Rizzu |l Applied Genomics for Neurodegenerative Diseases |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1210002 |k AG Heutink 1 |l Genome Biology of Neurodegenerative Diseases |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1210009 |
| 980 | _ | _ | |a I:(DE-2719)1210002 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|